Frank T. Watkins - Jan 20, 2023 Form 4 Insider Report for Shockwave Medical, Inc. (SWAV)

Role
Director
Signature
/s/ Wade Estey, as attorney-in-fact for Frank T. Watkins
Stock symbol
SWAV
Transactions as of
Jan 20, 2023
Transactions value $
-$522,272
Form type
4
Date filed
1/23/2023, 07:16 PM
Previous filing
Jan 10, 2023
Next filing
Feb 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SWAV Common Stock Options Exercise $6.59K +3K +79.03% $2.20 6.8K Jan 20, 2023 Direct F1
transaction SWAV Common Stock Sale -$86.3K -500 -7.36% $172.67 6.3K Jan 20, 2023 Direct F1, F2
transaction SWAV Common Stock Sale -$69.9K -400 -6.35% $174.70 5.9K Jan 20, 2023 Direct F1, F3
transaction SWAV Common Stock Sale -$373K -2.1K -35.62% $177.45 3.8K Jan 20, 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SWAV Stock Option Options Exercise $0 -3K -28.6% $0.00 7.49K Jan 20, 2023 Common Stock 3K $2.20 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/7/2022.
F2 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $172.50 to $172.78. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F3 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $174.29 to $175.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F4 All reported securities were sold at a price of $177.45.
F5 Twenty-five percent of the shares subject to the option vested on 5/20/16 and the balance of the shares vested in equal monthly installments thereafter for 36 months.